# Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried

> **NCT07357545** · PHASE3 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 2040 (actual)

## Conditions studied

- Rabies (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** Sinovac rabies vaccine
- **BIOLOGICAL:** Marketed rabies vaccine

## Key facts

- **NCT ID:** NCT07357545
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-27
- **Primary completion:** 2022-09-21
- **Final completion:** 2023-06-21
- **Target enrollment:** 2040 (ACTUAL)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07357545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07357545, "Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07357545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*